June 28, 2016: Infinity Pharma announced today that North Chicago-based AbbVie chose to terminate its collaboration deal to develop and commercialize duvelisib.
June 28, 2016: Mayne Pharma announced it will be acquiring 37 approved drugs and five products that have been filed with the FDA from Teva and Allergan.
June 28, 2016: Xencor announced today that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb13676.
June 28, 2016: Regulus today announced it received verbal notice from the FDA that its IND for RG-101 for the treatment of chronic hepatitis C virus infection has been placed on clinical hold. Regulus anticipates it will receive a formal clinical hold letter from the FDA within 30 days.